SBI Trans-Science

The firm builds formal pipelines through memoranda of understanding with Japanese national universities and public research institutes. It identifies technologies at the laboratory stage — particularly from JAXA, NEDO-funded programs, and top engineering faculties — that are approaching commercial readiness. This structured, non-intermediated model gives it visibility into deep-tech startups before they engage broad venture processes.

It operates as a specialized unit within the SBI Holdings group ecosystem, not as a standalone fund with third-party limited partners. The parent company, a publicly traded Tokyo conglomerate, allocates capital from its own balance sheet to Trans-Science’s activities. This means investment decisions ultimately roll up through SBI’s corporate governance structure.

The firm focuses on seed and early-stage equity, typically entering at the point where academic research transitions into a commercial prototype. It does not operate as a late-stage growth investor. Its positioning is closer to a technology-transfer acceleration model than a conventional venture capital fund, co-investing alongside government R&D grants and corporate partners.

The mandate concentrates on deep-tech domains where Japan holds strong public-sector R&D heritage: space technologies, robotics and automation, autonomous mobility systems, enterprise AI, and cybersecurity. It does not pursue the fintech, biotech, or consumer internet opportunities that SBI’s broader venture funds actively cover, maintaining a clean mandate separation.

Ultimate authority rests with Yoshitaka Kitao as Representative Director and Chairman of SBI Holdings. Day-to-day investment committee composition has not been publicly detailed, but as a wholly internal unit rather than an independent GP-LP structure, decisions follow SBI’s internal corporate approval hierarchy rather than an external limited-partner advisory board.

Based on available public disclosures, Trans-Science deploys SBI Holdings’ own capital and does not solicit external limited partners. This captive structure provides flexibility on hold periods and exit timing that an externally raised fund with fixed duration would not have, but also means its scale is directly tied to SBI’s allocation appetite.

SBI Group runs one of Japan’s largest venture capital platforms, historically weighted toward fintech, internet, and financial infrastructure. Trans-Science was carved out as a distinct unit to pursue a parallel thesis — monetizing Japan’s publicly funded deep technology research. The two track maintain separate investment pipelines and sector mandates, with Trans-Science deliberately positioned outside the group’s mass-scale venture fund structure.